Podcasts about Ellipses

La révolution industrielle au 19e siècle, est-ce que c'est un avancée ou un traumatisme qui nous habite encore ? Note: merci à @EdwinVan57 de l'avoir souligné. En 1871 la France a perdu l'Alsace et la Moselle et non la Lorraine entière.  Adhérez à cette chaîne pour obtenir des avantages : https://www.youtube.com/channel/UCN4TCCaX-gqBNkrUqXdgGRA/join Script: Maxime Testart de @laratplace et Laurent Turcot https://www.youtube.com/@laratplace Montage et réalisation: Laurent Turcot Pour soutenir la chaîne, au choix: 1. Cliquez sur le bouton « Adhérer » sous la vidéo. 2. Patreon: https://www.patreon.com/hndl 00:00 Introduction 02:30 C'est quoi la Révolution industrielle ? 06:14 Les origines au 18e siècle 12:23 Pourquoi la Grande-Bretagne ? 23:04 Des innovations qui changent le monde 29:30 Toujours plus vite et plus loin 33:31 Des villes industrielles 41:29 Deuxième révolution industrielle 46:17 Une source de conflits 56:05 Conclusion Musique issue du site : epidemicsound.com Images provenant de https://www.storyblocks.com Abonnez-vous à la chaine: https://www.youtube.com/c/LHistoirenousledira Les vidéos sont utilisées à des fins éducatives selon l'article 107 du Copyright Act de 1976 sur le Fair-Use. Sources et pour aller plus loin: Roland Marx, La révolution industrielle en Grande-Bretagne, Paris, Armand Colin, 1992 (1970). Nadège Sougy et Patick Verley, « La première industrialisation (1750-1880) » Documentation photographique, janvier-février 2008 Patrick Verley, La révolution industrielle, Paris, Gallimard, 1997 (1985). Jean-Pierre Rioux, La révolution industrielle 1780-1880, Paris, 1989 (1971). Chantal Beauchamp. Révolution industrielle et croissance économique au 19e siècle, Paris, Ellipses, 1997. Jean-Pierre Rioux et Dominique Redor, La révolution industrielle en Grande-Bretagne, Paris, Hatier, 1980. J.M. Roberts et O.A. Westad, Histoire du monde. 3. L'Âge des révolutions, Paris, Perrin, 2016. Joel Mokyr (dir.), The British Industrial Revolution: An Economic Perspective, Westview Press, 2018. Riello, Giorgio. Cotton: The Fabric That Made the Modern World. Cambridge: Cambridge University Press, 2013. E. P. Thompson, The Making of the English Working Class, Vintage, 1980 (1963). Smith, Bonnie G. et al. World in the Making: A Global History. New York: Oxford University Press, 2019. Jürgen Osterhammel, La transformation du monde, une histoire globale du XIXe siècle, Paris, Nouveau Monde. 2017 (2009 Louis Chevalier, Classes laborieuses et classes dangereuses pendant la première moitié du XIXe siècle, Paris, Plon, 1958. E. J. Hobsbawm, Histoire économique et sociale de la Grande-Bretagne. tome 2, de la révolution industrielle à nos jours, Paris, Seuil, 1977 (1968). E. J. Hobsbawm, Industry and Empire: From 1750 to the Present Day. 1999. Sidney Pollard, Peaceful Conquest: The Industrialization of Europe, 1760–1970, Oxford, Oxford University Press, 1981. David S. Landes, Richesse et pauvreté des nations. Pourquoi des riches ? Pourquoi des pauvres ?, Paris, Albin Michel, 2000 (1998) Jean-Charles Asselain, Histoire économique de la France du XVIIIe siècle à nos jours. Paris, Points, 2011, (1984), Emma Griffin, A Short History of the British Industrial Revolution, London, Bloomsbury, 2010. N. F. R. Crafts, British Economic Growth during the Industrial Revolution, Clarendon Press, 1985 François Crouzet, Histoire de l'économie européenne, 1000-2000, Albin Michel, Paris, 2000 Paul Bairoch, Révolution industrielle et sous-développement, Paris, éd. de l'E.H.E.S.S., 1974 (1963). https://fr.wikipedia.org/wiki/Puddlage Jean-Charles Asselain, « Révolution industrielle » [en ligne]. In Encyclopædia Universalis. Disponible sur : https://www-universalis-edu-com.biblioproxy.uqtr.ca/encyclopedie/revolution-industrielle/ Samir Amin. « Industrie » - Industrialisation et formes de société [en ligne]. In Encyclopædia Universalis. Francis Demier. « Multiplication des inventions » [en ligne]. In Encyclopædia Universalis. https://www.geo.fr/histoire/quest-ce-que-la-revolution-industrielle-208173 « LA RÉVOLUTION INDUSTRIELLE | Je révise avec toi | #08 », Je révise avec toi, 8 mars 2023. « LA SECONDE RÉVOLUTION INDUSTRIELLE | Je révise avec toi | #40 », Je révise avec toi, 7 mai 2023. « Révolution industrielle : Le Charbon, Moteur de la Puissance Britannique | Partie 1 | SLICE HISTOIRE », SLICE Histoire, 30 septembre 2024. « L'Industrialisation », RÉCIT Univers social, 20 août 2019. « L'HISTOIRE PAR L'IMAGE | La révolution industrielle », Grand Palais, 2 octobre 2020. « Coal, Steam, and The Industrial Revolution: Crash Course World History #32 » CrashCourse, 20 août 2012. Autres références disponibles sur demande. #histoire #documentaire #revolutionindustrielle #revolutionaryinventions #industrialrevolution #industrialrevolution

Killer plants! A murder mystery! Scheming agronomists! Ellipses…sentence fragments…and exclamation marks! EVERYWHERE! And so much new vocab! Come join Tony Whitt, Alyson Fitch-Safreed, Dalton Hughes, and special guest Matthew Kresal as they discuss Pip and Jane Baker's TERROR OF THE VERVOIDS!!! We are a proud part of the Direction Point Podcast Network, including such fine shows as THE DOCTOR WHO COLLECTORS PODCAST, THE POLICE BOX IN A JUNKYARD PODCAST, and TIMESTREAMS. You can check out these and other podcasts in the network at http://www.directionpoint.org! If you like what you hear, please come visit our Patreon page! It's at https://www.patreon.com/DWTargetBC. If you decide to support us in our ongoing effort to discuss all of the DOCTOR WHO novelizations, you'll be able to choose a gift! Contributing at any level gets you our extras! Visit the site for more details! We also have a book discussion group of our very own on Goodreads! It can be found at the link below. If you want to have your question, discussion, or review of a given book read aloud by us, simply join the group, post your response to the group by the given deadline, and we will see it! Also, feel free to follow us on the social media accounts listed below, or subscribe to us via the podcast provider of your choice. You can also email us at the email address given at the end of the episode with the phrase “Target Book Club” in the subject line! Thanks as always to Ron Schiding for our podcast logo and artwork, and to Dalton Hughes for the editing! Facebook: https://www.facebook.com/DoctorWhoTargetBookClubPodcast Instagram: https://www.instagram.com/doctorwhotargetbc/ Bluesky: https://bsky.app/profile/dwtargetbc.bsky.social iTunes: https://podcasts.apple.com/us/podcast/doctor-who-target-book-club-podcast/id1195364046?see-all=reviews SoundCloud: https://soundcloud.com/doctorwhotargetbc TuneIn: https://tunein.com/podcasts/Fantasy--Science-Fiction-Podc/Doctor-Who-Target-Book-Club-Podcast-p957128/ Goodreads: https://www.goodreads.com/group/show/710804-doctor-who-target-book-club-podcast The DIRECTION POINT Doctor Who Podcast Network: https://directionpoint.org/

La résilience est un processus de transformation de soi lorsque nous avons souffert de blessures psychologiques et de traumatismes complexes. Mais, nous ne sommes pas tous égaux face à ce processus de résilience. Comment le favoriser ? On en parle avec Christine Calonne, psychologue psychothérapeute et auteure de L'art de la résilience (Ed. Ellipses). Merci pour votre écoute Tendances Première, c'est également en direct tous les jours de la semaine de 10h à 11h30 sur www.rtbf.be/lapremiere Retrouvez tous les épisodes de Tendances Première sur notre plateforme Auvio.be : https://auvio.rtbf.be/emission/11090 Et si vous avez apprécié ce podcast, n'hésitez pas à nous donner des étoiles ou des commentaires, cela nous aide à le faire connaître plus largement.

Le FBI enquête sur les liens terroristes de l'attaque à la voiture-bélier d'un ancien militaire américain qui a fait au moins 15 morts et une trentaine de blessés le 1er janvier à La Nouvelle-Orléans (Louisiane). Les interrogations sont de plus en plus nombreuses sur la sécurisation du quartier très touristique où l'attaque s'est produite durant la nuit du Nouvel An. Le suspect présumé, décoré au titre de la lutte contre le terrorisme, avait un drapeau du groupe État islamique dans son véhicule. Décryptage de la menace jihadiste qui pèse sur les États-Unis avec Alain Rodier, ancien officier supérieur des renseignements extérieurs et directeur adjoint du Centre français de recherche sur le renseignement. Il a participé à l'ouvrage collectif La géopolitique au défi de l'islamisme (éditions Ellipses).

The Daily Quiz - Science and Nature Today's Questions: Question 1: Who was the German astronomer who discovered in the early 17th century that the planets orbit the sun in ellipses? Question 2: According to Boyle's Law, what increases when a gas is compressed to half its size? Question 3: What is Edaphology the study of? Question 4: On the Internet, what file extension is used for the content of web pages? Question 5: What is the name of the first spacecraft to land on the moon? Question 6: What is a terrapin? Question 7: What is the name of the second-largest planet in our solar system? Question 8: The moons Deimos and Phobos orbit which planet in our solar system? Question 9: What is the word for a male pig? This podcast is produced by Klassic Studios Learn more about your ad choices. Visit megaphone.fm/adchoices

AniTAY Podcast S9 E21: It's Ellipses STUPID The hardest part about watching anime for some of AniTAY is when it gets scientific facts wrong. It gets so bad that some can't stop TYPING IN ALL CAPS. This episode's members: Requiem, Gugsy, Hybridmink, and DocKev with Thatsmapizza handling the editing duties. The AniTAY Podcast is a bi-weekly podcast brought to you every other Wednesday. It is available on all your favorite podcast services! If you like us, be sure to subscribe to your favorite service and give us 5 stars! Your support is much appreciated and will help us grow and continue to provide this style of content. Intro: 0:00 - 1:04 Housekeeping: 1:05 - 6:19 2024 Seasonal Shows: Orb - On The Moments of Earth: 6:20 - 10:03 Mecha-Ude: 10:04 - 12:40 Metaphor ReFantazio: 12:41 - 22:26 Demonlord 2099: 22:27 - 24:13 Dandadan: 24:14 - 31:24 Loner Life in Another World: 31:25 - 34:56 Mushroom Pup: 34:57 - 39:06 Blue Box: 39:07 - 44:29 Arcane - A League of Legends Story: 44:30 - 50:24 News:  Visual Novels that are Getting Remastered, Ever 17 and Never 7: 50:25 - 54:56 NISA America Doesn't Plan to Produce any more Physical Media: 54:57 - 1:01:18 Question of the Week - Things We are Thankful For: 1:01:19 - 1:23:37 Ontro:1:23:38 - End Missed the previous episode of the AniTAY Podcast? Check it out here: https://medium.com/anitay-official/anitay-podcast-s9-e20-without-the-actual-gushing-6d956c42de10

Why are boomer-adjacents so bad at using ellipses? Hour 4 10/22/2024 full 2017 Tue, 22 Oct 2024 22:00:08 +0000 qmccgJ3z7YNFJv5CdsCnJXCkIDf6Oj3X news The Dana & Parks Podcast news Why are boomer-adjacents so bad at using ellipses? Hour 4 10/22/2024 You wanted it... Now here it is! Listen to each hour of the Dana & Parks Show whenever and wherever you want! 2024 © 2021 Audacy, Inc. News False https://player.amperwave

Vladimir Poutine réunit une vingtaine de dirigeants étrangers à partir de ce mardi pour le sommet des Brics, à Kazan, en Russie. Le président a convié les pays émergents pour consolider une alternative aux alliances occidentales. Il s'agit de montrer par la même occasion que la Russie n'est pas isolée sur la scène internationale depuis l'invasion de l'Ukraine. Le sommet réunit deux douzaines de dirigeants mondiaux, dont le Chinois Xi Jinping, l'Indien Narendra Modi, le Turc Recep Tayyip Erdogan et l'Iranien Massoud Pezeshkian. L'analyse d'Alexandre Kateb, économiste, fondateur de Multipolarity.AI et auteur de Les nouvelles puissances mondiales. Pourquoi les Brics changent le monde (édition Ellipses).

Danielle was joined by Dominique Morgan, activist and prison abolitionist, to talk about her work and life journey - including being the first openly trans Black woman to have a street named after her.See omnystudio.com/listener for privacy information.

Vincent Czeszynski, associé chez EY-Parthenon, est l'auteur du livre « Climat, 20 questions pour comprendre et agir », paru aux éditions Ellipses en juin 2024. La décroissance est-elle souhaitable ? Le carbone doit-il avoir un prix ? Les normes environnementales sont-elles trop nombreuses ? Voici les principales questions controversées auxquelles il répond dans SMART IMPACT.-----------------------------------------------------------------------SMART IMPACT - Le magazine de l'économie durable et responsableSMART IMPACT, votre émission dédiée à la RSE et à la transition écologique des entreprises. Découvrez des actions inspirantes, des solutions innovantes et rencontrez les leaders du changement.

L'Assemblée générale de l'ONU se saisit ce jeudi (21 mars 2024) du débat de l'intelligence artificielle. Une première résolution appelant à la mise en place de normes internationales a été adoptée. La question de la régulation est vive alors que l'IA se développe au pas de charge. La semaine dernière, le Parlement européen a adopté la première législation au monde en la matière. Régulation et innovation peuvent-elles aller de pair ? Faut-il accepter de ne pas avoir totalement la main sur ces technologies du futur ? L'Europe est-elle vouée à être distancée par les États-Unis et la Chine ? Pour en débattre :- Nicolas Sabouret, directeur de la Graduate School « Informatique et sciences du numérique » à l'Université Paris-Saclay, enseignant à CentraleSupélec. Chercheur en IA, auteur du livre Comprendre l'IA, éditions Ellipses, co-auteur de l'ouvrage L'intelligence artificielle n'est pas une question technologique, éditions l'Aube- Georges Nahon, expert des Technologies numériques, ancien directeur du Centre d'innovation d'Orange Silicon Valley à San Francisco (pendant 15 ans), conférencier et co-auteur du livre Le village numérique mondial : la deuxième vie des réseaux, Éditions Odile Jacob- Sandro Gozi, député européen Renew Europe, secrétaire général du parti démocrate européen.

L'Assemblée générale de l'ONU se saisit ce jeudi (21 mars 2024) du débat de l'intelligence artificielle. Une première résolution appelant à la mise en place de normes internationales a été adoptée. La question de la régulation est vive alors que l'IA se développe au pas de charge. La semaine dernière, le Parlement européen a adopté la première législation au monde en la matière. Régulation et innovation peuvent-elles aller de pair ? Faut-il accepter de ne pas avoir totalement la main sur ces technologies du futur ? L'Europe est-elle vouée à être distancée par les États-Unis et la Chine ? Pour en débattre :- Nicolas Sabouret, directeur de la Graduate School « Informatique et sciences du numérique » à l'Université Paris-Saclay, enseignant à CentraleSupélec. Chercheur en IA, auteur du livre Comprendre l'IA, éditions Ellipses, co-auteur de l'ouvrage L'intelligence artificielle n'est pas une question technologique, éditions l'Aube- Georges Nahon, expert des Technologies numériques, ancien directeur du Centre d'innovation d'Orange Silicon Valley à San Francisco (pendant 15 ans), conférencier et co-auteur du livre Le village numérique mondial : la deuxième vie des réseaux, Éditions Odile Jacob- Sandro Gozi, député européen Renew Europe, secrétaire général du parti démocrate européen.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UFJ865. CME/MOC/AAPA/IPCE credit will be available until March 23, 2025.Peer Pressure: How Well Do You Know Your ADCs? Cracking the Code of Targeted Delivery of Cytotoxic Payloads in Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerMarina Chiara Garassino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; OSE Immunotherapeutics; Pfizer; Regeneron Pharmaceuticals Inc.; Seattle Genetics, Inc.; and Takeda Pharmaceutical Company Ltd.Grant/Research Support from Research funding to institution for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; Lilly; Merck Sharp & Dohme Corp.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Spectrum Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Ltd.Speaker for AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Mirati Therapeutics, Inc.; MSD International GmbH; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Ltd/Mirati Therapeutics, Inc.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; Puma Biotechnology, Inc.; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Faculty/PlannerZosia Piotrowska, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Bayer Corporation; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Sanofi; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Grant/Research Support from AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Cullinan Oncology, Inc; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and Tesaro, Inc./GlaxoSmithKline.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

"M

"M

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/YXT865. CME/MOC/AAPA credit will be available until January 2, 2025.Under Pressure to Improve: How to Unlock the Power of Antibody–Drug Conjugates to Transform the Treatment of Lung Cancer In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Sanofi.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Medicines Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo Inc./AstraZeneca; Eisai Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./sanofi-aventis U.S. LLC; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; MacroGenics, Inc.; and Merck Sharp & Dohme LLC.Faculty/PlannerRebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Claim Therapeutics; Daiichi Sankyo, Inc.; EMD Serono Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AbbVie Inc.; Daiichi Sankyo, Inc.; Erasca, Inc.; Lilly; Mirati Therapeutics, Inc.; Mythic Therapeutics; Novartis Pharmaceuticals Corporation; Symphogen; and Turning Point Therapeutics, Inc. All to institution.Faculty/PlannerStephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Catalyst Pharmaceuticals Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Elevation Oncology, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Merus; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceutical Company Limited; and Turning Point Therapeutics, Inc.Grant/Research Support from AbbVie Inc.; Alkermes; Elevation Oncology, Inc.; Ellipses; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Merus; Nuvalent; RAPT Therapeutics; and Turning Point Therapeutics, Inc.Data Safety Monitoring Board for Candel Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Mike hates ellipses.... Tim responds.... #grammar #metallica #megadeth #falkenbach PODCAST THEM DOWN - https://linktr.ee/pctdhttps://patreon.com/podcastthemdown STEEL RESOLVE Bands - https://linktr.ee/steelresolve Including BURNING SHADOWS [US Power Metal], ISENMOR [Folk Metal], FADE TO BLACK [Metallica Tribute], RECENTLY VACATED GRAVES: TRUE ZOMBIE METAL [Zombie Metal], and more!

Jusqu'en 1950, l'Algérie est le plus grand exportateur de vin au monde ! Dom Pérignon n'a pas inventé le Champagne tel qu'on le connaît ! La bouteille en verre a tout changé ! Pour en savoir plus sur ces trois affirmations, écoutez notre 3è et dernier volet sur l'Histoire du Vin, de la Renaissance à nos jours. En effet, à la fin du Moyen-Âge, les moines perfectionnèrent la viticulture, tandis que le commerce international se développa. Au XVIIe siècle, la France devint le centre mondial de la viticulture avec l'apparition des vignobles de Bordeaux et de Bourgogne. Au XIXe siècle, la phylloxéra ravagea les vignes européennes, entraînant des replantations massives et des innovations techniques. Le vin devint un symbole de prestige, avec l'apparition des grands crus. Le XXe siècle vit l'essor de l'industrie vinicole, la mondialisation des goûts et la popularisation du vin en dehors de l'Europe. Les Nouveaux Mondes, comme l'Australie et la Californie, produisirent des vins de renom. Aujourd'hui, la viticulture durable et biologique gagne du terrain, tout comme la technologie moderne dans la production. Le vin est plus accessible que jamais, avec des vignobles du monde entier offrant une grande variété de saveurs, de cépages et de styles. Il est devenu un élément incontournable de la culture mondiale, célébré à travers des festivals, des dégustations et des discussions passionnées.

Jusqu'en 1950, l'Algérie est le plus grand exportateur de vin au monde ! Dom Pérignon n'a pas inventé le Champagne tel qu'on le connaît ! La bouteille en verre a tout changé ! Pour en savoir plus sur ces trois affirmations, écoutez notre 3è et dernier volet sur l'Histoire du Vin, de la Renaissance à nos jours. En effet, à la fin du Moyen-Âge, les moines perfectionnèrent la viticulture, tandis que le commerce international se développa. Au XVIIe siècle, la France devint le centre mondial de la viticulture avec l'apparition des vignobles de Bordeaux et de Bourgogne. Au XIXe siècle, la phylloxéra ravagea les vignes européennes, entraînant des replantations massives et des innovations techniques. Le vin devint un symbole de prestige, avec l'apparition des grands crus. Le XXe siècle vit l'essor de l'industrie vinicole, la mondialisation des goûts et la popularisation du vin en dehors de l'Europe. Les Nouveaux Mondes, comme l'Australie et la Californie, produisirent des vins de renom. Aujourd'hui, la viticulture durable et biologique gagne du terrain, tout comme la technologie moderne dans la production. Le vin est plus accessible que jamais, avec des vignobles du monde entier offrant une grande variété de saveurs, de cépages et de styles. Il est devenu un élément incontournable de la culture mondiale, célébré à travers des festivals, des dégustations et des discussions passionnées.

Jusqu'en 1950, l'Algérie est le plus grand exportateur de vin au monde ! Dom Pérignon n'a pas inventé le Champagne tel qu'on le connaît ! La bouteille en verre a tout changé ! Pour en savoir plus sur ces trois affirmations, écoutez notre 3è et dernier volet sur l'Histoire du Vin, de la Renaissance à nos jours. En effet, à la fin du Moyen-Âge, les moines perfectionnèrent la viticulture, tandis que le commerce international se développa. Au XVIIe siècle, la France devint le centre mondial de la viticulture avec l'apparition des vignobles de Bordeaux et de Bourgogne. Au XIXe siècle, la phylloxéra ravagea les vignes européennes, entraînant des replantations massives et des innovations techniques. Le vin devint un symbole de prestige, avec l'apparition des grands crus. Le XXe siècle vit l'essor de l'industrie vinicole, la mondialisation des goûts et la popularisation du vin en dehors de l'Europe. Les Nouveaux Mondes, comme l'Australie et la Californie, produisirent des vins de renom. Aujourd'hui, la viticulture durable et biologique gagne du terrain, tout comme la technologie moderne dans la production. Le vin est plus accessible que jamais, avec des vignobles du monde entier offrant une grande variété de saveurs, de cépages et de styles. Il est devenu un élément incontournable de la culture mondiale, célébré à travers des festivals, des dégustations et des discussions passionnées.

Jusqu'en 1950, l'Algérie est le plus grand exportateur de vin au monde ! Dom Pérignon n'a pas inventé le Champagne tel qu'on le connaît ! La bouteille en verre a tout changé ! Pour en savoir plus sur ces trois affirmations, écoutez notre 3è et dernier volet sur l'Histoire du Vin, de la Renaissance à nos jours. En effet, à la fin du Moyen-Âge, les moines perfectionnèrent la viticulture, tandis que le commerce international se développa. Au XVIIe siècle, la France devint le centre mondial de la viticulture avec l'apparition des vignobles de Bordeaux et de Bourgogne. Au XIXe siècle, la phylloxéra ravagea les vignes européennes, entraînant des replantations massives et des innovations techniques. Le vin devint un symbole de prestige, avec l'apparition des grands crus. Le XXe siècle vit l'essor de l'industrie vinicole, la mondialisation des goûts et la popularisation du vin en dehors de l'Europe. Les Nouveaux Mondes, comme l'Australie et la Californie, produisirent des vins de renom. Aujourd'hui, la viticulture durable et biologique gagne du terrain, tout comme la technologie moderne dans la production. Le vin est plus accessible que jamais, avec des vignobles du monde entier offrant une grande variété de saveurs, de cépages et de styles. Il est devenu un élément incontournable de la culture mondiale, célébré à travers des festivals, des dégustations et des discussions passionnées.

Jusqu'en 1950, l'Algérie est le plus grand exportateur de vin au monde ! Dom Pérignon n'a pas inventé le Champagne tel qu'on le connaît ! La bouteille en verre a tout changé ! Pour en savoir plus sur ces trois affirmations, écoutez notre 3è et dernier volet sur l'Histoire du Vin, de la Renaissance à nos jours. En effet, à la fin du Moyen-Âge, les moines perfectionnèrent la viticulture, tandis que le commerce international se développa. Au XVIIe siècle, la France devint le centre mondial de la viticulture avec l'apparition des vignobles de Bordeaux et de Bourgogne. Au XIXe siècle, la phylloxéra ravagea les vignes européennes, entraînant des replantations massives et des innovations techniques. Le vin devint un symbole de prestige, avec l'apparition des grands crus. Le XXe siècle vit l'essor de l'industrie vinicole, la mondialisation des goûts et la popularisation du vin en dehors de l'Europe. Les Nouveaux Mondes, comme l'Australie et la Californie, produisirent des vins de renom. Aujourd'hui, la viticulture durable et biologique gagne du terrain, tout comme la technologie moderne dans la production. Le vin est plus accessible que jamais, avec des vignobles du monde entier offrant une grande variété de saveurs, de cépages et de styles. Il est devenu un élément incontournable de la culture mondiale, célébré à travers des festivals, des dégustations et des discussions passionnées.

Jusqu'en 1950, l'Algérie est le plus grand exportateur de vin au monde ! Dom Pérignon n'a pas inventé le Champagne tel qu'on le connaît ! La bouteille en verre a tout changé ! Pour en savoir plus sur ces trois affirmations, écoutez notre 3è et dernier volet sur l'Histoire du Vin, de la Renaissance à nos jours. En effet, à la fin du Moyen-Âge, les moines perfectionnèrent la viticulture, tandis que le commerce international se développa. Au XVIIe siècle, la France devint le centre mondial de la viticulture avec l'apparition des vignobles de Bordeaux et de Bourgogne. Au XIXe siècle, la phylloxéra ravagea les vignes européennes, entraînant des replantations massives et des innovations techniques. Le vin devint un symbole de prestige, avec l'apparition des grands crus. Le XXe siècle vit l'essor de l'industrie vinicole, la mondialisation des goûts et la popularisation du vin en dehors de l'Europe. Les Nouveaux Mondes, comme l'Australie et la Californie, produisirent des vins de renom. Aujourd'hui, la viticulture durable et biologique gagne du terrain, tout comme la technologie moderne dans la production. Le vin est plus accessible que jamais, avec des vignobles du monde entier offrant une grande variété de saveurs, de cépages et de styles. Il est devenu un élément incontournable de la culture mondiale, célébré à travers des festivals, des dégustations et des discussions passionnées.

Episode: 2827 Dimensionless groups, helping us to deal with the similarity of often very different situations.  Today, dimensionless groups.

La décision d'élargir les Brics a été prise lors du sommet qui s'est tenu à Johannesburg entre le 22 et le 24 août. Argentine, Égypte, Éthiopie, Arabie Saoudite, Iran et Émirats Arabes Unis rejoindront le bloc dès le début de l'année prochaine dans le cadre d'une première phase d'expansion. Un élargissement qui laisse aussi 17 pays à la porte et confirme le rôle croissant de la Chine dans l'organisation sur fond de divergences entre pays du noyau dur. À Johannesburg, se sont affrontées deux manières de revoir le multilatéralisme obsolète, la gouvernance de la Banque Mondiale et du Fonds Monétaire International et des ambitions parfois difficiles à concilier au sein d'un groupe aussi hétérogène politiquement qu'économiquement. Si certains États sont opposés à l'hégémonie occidentale, ils ne sont pas encore d'accord entre eux sur ce que devrait être la nouvelle alternative. Que va changer cet élargissement ? Quelles dynamiques nouvelles vont se mettre en place ?Invités :  Joan Deas, Directrice exécutive de l'Institut de recherche et d'études Méditerranée Moyen-Orient ('IREMMO). Do BRICS Countries Want to Shape a New World Order, Revue Internationale et Stratégique n°130 Alexandre Kateb, économiste. Fondateur du cabinet de prospective The Multipolarity Report. Les nouvelles puissances mondiales. Pourquoi les BRICS changent le monde aux éditions Ellipses. Les économies arabes en mouvement aux editions de Boeck. 

Du 22 au 24 août 2023, se tient à Johannesbourg le sommet annuel des Brics… Brics, acronyme anglais pour Brésil, Russie, Inde, Chine et Afrique du Sud. Sa création remonte à la première décennie des années 2000 comme une sorte d'alternative à l'hégémonie américaine et à l'unipolarité et ce sentiment profond qui unit ces cinq pays d'avoir été maintenus à la périphérie des affaires politiques du monde par les puissances occidentales. Les seuls BRICS pèsent désormais davantage que les membres du G7 dans l'économie mondiale, la Chine y étant pour une bonne part.Le sommet de Johannesbourg s'inscrit dans le contexte tendu de la guerre d'Ukraine et des sanctions qui pèsent sur la Russie, de rivalité sino-américaine prononcée, d'affirmation de l'Inde voire d'émergence sur la scène mondiale, du retour de Lula à Brasilia sur fond de volonté de faire du Brésil une puissance régionale forte, enfin d'alliance russo-chinoise, dont il n'est pas toujours facile de mesurer la profondeur. L'ordre mondial post-guerre froide continue de se désorganiser, la puissance se diffuse. Nombreux sont les candidats à une intégration au sein des BRICS, économique et politique.  Invités :   Julien Vercueil, professeur d'Économie et vice-président de l'Institut National des Langues et Civilisations Orientales, l'INALCO. « Les pays émergents. Brésil-Russie-Inde-Chine. Mutations économiques. Crises et nouveaux défis », éd. Bréal et « Économie politique de la Russie », Seuil. Coll. Points   Thierry Vircoulon, chercheur associé à l'IFRI. « Les sanctions économiques contre la Russie » Revue Esprit juillet 2023 Alexandre Kateb, économiste, fondateur du cabinet de prospective « The Multipolarity Report ». « Les nouvelles puissances mondiales. Pourquoi les BRICS changent le monde », éd. Ellipses. « Les économies arabes en mouvement », éd. De Boeck.

Pour yourself something to sip while we pour an intellectual vacation in your ears. Work is work. Overpaying for menial labor. No bitchy bitchy to or about Jeff. Calendar countdowns. He really is afraid of Jeff. Independently-thinking legs are no fun. Sequuuuuuuuuuue Memes The 2nd Rodeo Meal prep and children A gator doing gator things. MMA fighter doing MMA fighter things to a gator. Jarhead doing jarhead things to a gator. Licensed gator trapper doing licensed gator trapper things to a gator He's the same guy...and he had help. It's like déjà vu all over again. Jeff is still a nerdy teen. How to get to a beatdown. Pedanticles makes an appearance. The Whiskey Hell Podcast makes a contribution. Old school words that should never have gone out of style. Ultracrepidarian KAKISTOCRACY Hard "g" or soft "g"? Fudgel (is it a noun? a verb?) Tax revenues are a little hard to come by these days. Ellipses can be drops of sarcasm. Who's to blame for the melodramatic headline? The early iterations of Skynet make an appearance. Creators & Guests Jeff Feightner - Host Chris Dubbelde - Host If you're ready to make a podcast, make your podcast better or collaborate in another way, contact us at makemypod@fytepro.com

Hear the powerfully poetic Beloved! Paradise! Jazz!? from McKinley Dixon, a scorcher from Bully, Aisha Badru's Learning to Love Again, the first new solo album in 15 years from Ben Folds and more.Featured Albums:1. McKinley Dixon — Beloved! Paradise! Jazz!?Featured Songs: "Run, Run, Run," "Hanif Reads Toni," "Live! From the Kitchen Table (feat. Ghais Guevara)"2. Bully — Lucky For YouFeatured Songs: "Hard to Love," "Lose You (feat. Soccer Mommy)," "All I Do"3. Aisha Badru — Learning to Love AgainFeatured Songs: "Path of Least Resistance," "Inside," "Move"4. Ben Folds — What Matters MostFeatured Songs: "What Matters Most," "Clouds with Ellipses," "Kristine from the 7th Grade," "Moments (feat. Tall Heights)"5. W.I.T.C.H. — ZangoFeatured Songs: "Waile," "Avalanche of Love (feat. Sampa the Great)"Lightning Round:Foo Fighters — But Here We AreJuan Wauters — Wandering RebelLazy Salon — BellisToosii — NAUJOUROther notable releases for June 2:The Aquadolls — CharmedBob Dylan — Shadow KingdomCowboy Junkies — Such Ferocious BeautyJack Johnson — In Between DubKenny Rogers — Life is Like a SongLinda May Han Oh — The Glass HoursMoneybagg Yo — Hard to LoveNoel Gallagher's High Flying Birds — Council SkiesProtomartyr — FormalRufus Wainwright — FolkocracyTanya Tucker — Sweet Western Sound

Un peu d'histoire des mathématiques, ça vous dit ? Ce mois-ci, Théo vous emmène à la découverte des nombres complexes ! Egalement appelés "imaginaires", ces nombres mystérieux ont été théorisés pour résoudre des problèmes pour lesquels les nombres dits "rationnels" ne suffisaient pas. La quête vers la découverte des nombres imaginaires fut semée d'embûches, créant même quelques disputes entre mathématiciens. Pour en savoir plus sur cette histoire croustillante, c'est par ici que ça se passe ! Bonne écoute ! Sources : Images, imaginaires, imaginations : Une perspective historique pour l'introduction de nombres complexes, IREM, 1998, Ellipses. Cours : Histoire de l'algèbre et de l'arithmétique, F.Lê, Université Lyon 1. Dans le secret des nombres, M. Freiberger et R. Thomas, 2018, Dunod. https://www.lelivrescolaire.fr/page/15117110. Cet épisode a été réalisé par Théo Pellarin et monté par Angélique Noël.

The Imperial War Museum in London is putting on display recently collected objects and new first-hand testimony describing life in Northern Ireland during The Troubles in its first show to look at this topic. Anne McElvoy explores what it means to explore this history in writing, music and museum displays. The author Louise Kennedy's novel Trespasses is a 1970s love story. Poet Maria McManus and composer Keith Acheson have collaborated on a piece called Ellipses which they describe as being about "doubling back and reclaiming the sense of wonder, awe and timelessness that came before all the grimness". And Maria Fusco has worked on a new opera film which highlights the experiences of working class women in Belfast. Producer: Robyn Read Louise Kennedy's books include the short story collection The End of the World is a Cul de Sac and a novel set during 1970s Belfast called Trespasses which is now out in paperback. Northern Ireland: Living with the Troubles is a free exhibition at the IWM London curated by Craig Murray Ellipses is being performed at the Belfast International Arts Festival in November History of the Present an opera film was made on 35mm and SD video in the streets of Belfast, the Ulster Museum and the Royal Opera House in London. It was co-directed by Maria Fusco and Margaret Salmon with music by composer Annea Lockwood and will be screened 24.06.23 at Art Night, Dundee 02.07.23 The Royal Opera House, London and 11.08.23 for the Edinburgh Art Festival [live version]

After Edda "cures" Amos's hiccups, he takes the stage, first without his cello (hilarious!) and then with it. His performance, which is of course watched via satellite by all of his family and friends, inspires so much passion, that Juliette fucks Elliott on the couch right next to Nan. It also inspires Isabel to have sex with her boyfriend and Seth to make up with Mark, who appears here as a doll or small child. Amos finishes his performance and everyone there loses their minds, throwing their programs in the air and then roses at Amos and Edda. Naturally, the judges unanimously award the grand prize to Amos, who honestly looks like he doesn't give a shit and would rather be anywhere else but there. The victory is short-lived because of the sex tape that everyone saw. You know, because that caused an unfair advantage. Amos asks for another juried performance and then fucks Edda at the press conference. And that's where we leave Brussels, because this just goes on and on and we've truly had enough. (Part 3 of 3) The Chickweed strips we discuss this episode: Two Belgian perverts listen to Amos & Edda have sex, Amos & Edda finish having sex, Amos forgets his cello, then Amos forgets he's at a competition are here (https://twitter.com/9chickweedRAGE/status/1627658453236981760?s=20). Amos & Edda begin their performance, the audience falls in love, Juliette & Elliott have sex next to Gran, and Isabel accosts her boyfriend are here (https://twitter.com/9chickweedRAGE/status/1627658456625991681?s=20). Seth reunites with Mark, the audience throws their programs, the audience throws roses, and Amos gives Edda a rose are here (https://twitter.com/9chickweedRAGE/status/1627658459931119619?s=20). Brooke Mac-El-Dee makes an ellipsis joke, Edda floats up to heaven, Amos and Edda get a phone call, and Edda finally has to tell Amos about the sex tape are here (https://twitter.com/9chickweedRAGE/status/1627658463382994944?s=20). Amos doesn't care about the sex tape and Amos & Edda have sex at a press conference are here (https://twitter.com/9chickweedRAGE/status/1627658466302230528?s=20). This award-winning, then award-losing episode includes: Drug commercials Resting heart rates The Actor's Nightmare Broadway Stupid computers Lurking outside doors Claude the Cat Showgirls Yo-Yo Ma performs Bach's Cello Suite No. 1 in G Major (https://www.youtube.com/watch?v=1prweT95Mo0). "Great Balls of Fire" (https://www.youtube.com/watch?v=F569_t2jCio) by Jerry Lee Lewis Poltergeist The clown scene is here (https://www.youtube.com/watch?v=BZOnLUt7OI4) and starts at 2:22. The vulva Sex in front of your mom Turtlenecks! Console TVs, much like this one (https://www.ebay.com/itm/174787590138?chn=ps&norover=1&mkevt=1&mkrid=711-117182-37290-0&mkcid=2&mkscid=101&itemid=174787590138&targetid=1262749491542&device=c&mktype=&googleloc=9031194&poi=&campaignid=14859008593&mkgroupid=130497710760&rlsatarget=pla-1262749491542&abcId=9300678&merchantid=6296724&gclid=Cj0KCQiAi8KfBhCuARIsADp-A55qOrLDnpRrQ2lb9akFKcqkCiQVzgDHs-4dkQ0WG44bXsm_nWKByFUaAtXSEALw_wcB). Raggedy Andy Doll Bats! Caligula Roses Melissa Manchester sings (https://www.youtube.com/watch?v=XGmYnKsuSh0) "Please Don't Let This Feeling End." Ellipses! E.T. More turtlenecks! Sweet Greens Souplantation Talk to Us! Having trouble understanding what's going on in a 9 Chickweed Lane strip you just read? Send it our way! We'll take a shot at interpreting it for you! Or maybe you just want someone to talk to? We're on Twitter: @9ChickweedRAGE (https://twitter.com/9chickweedRAGE)

Mercury must be in retrograde because Ellipses has finally found her way back to that absolute Fraud of a therapist Ian Herrin for another session! But alas, Ellipses you have to understand even though you don't want to kink shame, you can absolutely do better than to let this total Dexter looking murderous freak of a clitoris (ahem, I mean C.T.W.R.O.S.) tell you how to treat yourself when you're still recovering from a leprechaun encounter!! It is NOT okay for Ian to slide into your DMs or to Vader cosplay choke you. If you ever find a monkey's paw or claw, make sure you wish this face-loving freak never purports himself to be a therapist again. Did you follow the rainbow to this part of the episode description? Well lucky you, this part is the gold were I get to tell you all about comedian and drag performer Mikey Pobuda!! Be sure you follow Mikey on Tiktok @mikeypobuda and also you can find his drag persona on Instagram @ellipsisqueen in addition to the new Instagram for his twoprov team with legendary producer Nic Rockwell @sacboizcomedy --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/sigmund-fraud/support

"Adults, people with families, people with jobs: lifelong learning happens well beyond this discrete moment in your life when you're 18-20 years old. And people can reap the benefits of continuing education and furthering their certifications and degrees and experiences for their entire lives," Illinois Valley Community College instructor Delores Robinson.

Today we are discussing the first half of chapter 24 of Goblet of Fire, including: the chronic issue of incomplete allegories in these books, the true story of eye of newt, the introduction of cottage core dream witch Professor Grubbly-Plank, and so much more! Read about eye of newt and stuff here: people.howstuffworks.com/is-eye-of-newt-real-thing.htm PLEASE CONSIDER JOINING OUR PATREON! Due to Jessie's injury we are urgently working to increase our monthly pledges to $6666 per month, and that will only be possible with your support! Patreon.com/thegaylyprophet Lark's tarot deck, Under the Bed Tarot, is now available to preorder in our shop! https://hashtagruthless.com/shop/under-the-bed-tarot-preorder- Head to hashtagruthless.com to check out all of our new merch, and to help us out with transcriptions! Follow us on social media instagram.com/thegaylyprophet twitter.com/thegaylyprophet Show art is by Theo Julien Forrester Music from https://filmmusic.io "Industrial Music Box" by Kevin MacLeod (https://incompetech.com) License: CC BY (http://creativecommons.org/licenses/by/4.0/) -Edited from the original-

April 8, 2022 / Mom &… Podcast: Tipsy Ellipses Episode / Guest: Sarah Maizes Subscribe & Review wherever you listen to podcasts Show Summary Tipsy Ellipses is a monthly bonus episode that we record via Facebook Live. This month's live recording took place on Tuesday, April 5, and featured guest, Sarah Maizes. Sarah is an... The post Tipsy Ellipses with Guest Sarah Maizes appeared first on Mom And Podcast.